NasdaqCM - Nasdaq Real Time Price ? USD Quoin Pharmaceuticals, Ltd. (QNRX) Follow Compare 0.7519 -0.1127 (-13.03%) At close: October 22 at 4:00 PM EDT 0.7675 +0.02 (+2.07%) Pre-Market: 9:21 AM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a Clinical Research Organization Has Been Engaged Additional Sites in other Western European Countries are being Finalized ASHBURN, Va., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare GlobeNewswire ? yesterday QNRX -13.03% Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO Purchases Signal Leadership Confidence and Commitment to CompanyASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company’s American Depositary Shares (ADSs), signali GlobeNewswire ? last month QNRX -13.03% QNRX: Assessing QRX003 For Multiple Conditions; Opening International Netherton Syndrome Clinical Sites By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT International expansion of clinical trial sites for QRX003 study, beginning with Saudi Arabia… … Quoin Pharmaceuticals (NASDAQ:QNRX) has made numerous strides advancing its portfolio of assets to treat various rare and orphaned diseases. The company’s lead asset is QRX003, which currently is being evaluated for the treatment of Netherton Zacks Small Cap Research ? 2 months ago QNRX -13.03% Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in Rare and Orphan Diseases ASHBURN, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company foc GlobeNewswire ? 2 months ago QNRX -13.03% Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”) a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today a GlobeNewswire ? 2 months ago QNRX -13.03% Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. The announcement will provide an operational update regarding the company’s achievements during the quarter and will detail financial highlights. Abou GlobeNewswire ? 2 months ago QNRX -13.03% Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advanced Stage ASHBURN, Va., June 27, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announce GlobeNewswire ? 3 months ago QNRX -13.03% Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024. The three-day premier event is held every two years with the aim of connecting individuals seeking informati GlobeNewswire ? 3 months ago QNRX -13.03% Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery of rapamycin ASHBURN, Va., June 12, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced t GlobeNewswire ? 4 months ago QNRX -13.03% QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Protocol modifications could accelerate and/or expand QRX003 regulatory approvals … Quoin Pharmaceuticals (NASDAQ:QNRX) has two active Netherton Syndrome (NS) studies that are being conducted concurrently to evaluate lead asset QRX003 for the treatment of NS. Preliminary clinical data was positive. Five of six subjects evaluated had Zacks Small Cap Research ? 4 months ago QNRX -13.03% Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and a GlobeNewswire ? 5 months ago QNRX -13.03% Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024. The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights. About Qu GlobeNewswire ? 5 months ago QNRX -13.03% Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript March 14, 2024 Quoin Pharmaceuticals, Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Quoin Pharmaceuticals Fourth Quarter Financial Results and Business Update Conference Call. […] Insider Monkey ? 7 months ago QNRX -13.03% Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen years and older No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend into the second half of 2025 following $6.5 million offering on March 5th C GlobeNewswire ? 7 months ago QNRX -13.03% Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quart GlobeNewswire ? 7 months ago QNRX -13.03% QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Strengthening financial position to advance clinical studies… Quoin Pharmaceuticals (NASDAQ:QNRX) has completed a capital raise to strengthen its financial position in order to continue to move lead asset QRX003 and other candidates in its portfolio forward. As Quoin advances clinical studies to evaluate QRX003 for the treatment of Zacks Small Cap Research ? 7 months ago QNRX -13.03% Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,062,500 ordinary shares represented by 4,062,500 Americ GlobeNewswire ? 7 months ago QNRX -13.03% Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development represents the first ever inclusion of non-adult subjects in Netherton Syndrome clinical studies conducted under an open Investigational New Drug Application ASHBURN, Va., March 04, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDA GlobeNewswire ? 7 months ago QNRX -13.03% Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. This new product combines a broad spectrum serine protease inhibitor with GlobeNewswire ? 8 months ago QNRX -13.03% Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from blinded trialDosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has received U.S. Food and Drug Administr GlobeNewswire ? 10 months ago QNRX -13.03% Performance Overview Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is MSCI WORLD Return QNRX MSCI WORLD YTD -84.67% +17.51% 1-Year -82.55% 0.00% 3-Year -99.96% +18.18%
